© Low rik © Moderate risk @ High risk Very ah rk $$ _________ @rsr. WHO-regioni sa KV rizikom +2021 ESC Guidelines on cardiovascular disease prevention in clinical practice ee est 0‘SCORED & SCORED-OP toe rat tendo @eEsc ent poms VS Women Neri cmiatws | SCORE2 and SCORE2-OP Pore ee risk chart for fatal and 3S f) Boo non-fatal (MI, stroke) O@ $990 coiled oe a0 Very high CVD Risk (1) goo 239 9009 ~ 9000 000 [| 2000 9205 | 9900 0600 ,,, 9000 2909 “” 9909 goo a0 2609 | e000 3338 = Sees 8899 *" 3000 000 [| 9000 3 womeeceraio.rg/slstnes (Guropean tert Jurol 2021 €o30 053/urheari/ehabas) \\FSCIEAS GUDELNES ESC scares 6 2019 ESCIEAS Guidelines for the management of dyslipidaemia: lipid modification to reduce cardiovascular risk ‘The Task Force forthe management of dsiidaemias ofthe European Society of Cardiology (ESC) and European ‘Atherosclerosis Society (EAS) 1 Trane go wie ‘Table Candoracaar rie ctepoies ee wt org Seeraced er etdor most Satna Once SCV a po Nester ma ng ie mga roetaton PLEN wseat ‘Rittenene pce) sen areata puayraveyinl Imes ASC negro ‘hapten page coma po? Cheeni comney aman Ser ccratesctannungsncscmny a hcon rer oun OM io snace exam. sce XD PR m7) cane SSone et tyes nati Fie rah am rear ated slots i icon np Te Stnnoh (mp a Lee al Crore eon, econ x gOr0- 0 camer) Yarn (10% ps OM 9) (reucmaascont stn yer 2 Lentil CONE Rr Orr st OO,Koji statin i u kojoj dozi ? sACCIAHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults Ti emcees atone Daly ase Buus WERE Dy deeds on sarap fae ete Loo) average QO) tepeninetehGo-a) ian ‘Atorvastatin 40-80 mg ‘Atorvastatin 10-20 mg Simvastatin 10 mg Rosuvastatin 20-40 mg Rosuvastatin 5-10 mg Pravastatin 10-20 mg Simvastatin 20-40 mg Lovastatin 20 mg Pravastatin 40-80 mg Fluvastatin 20-40 mg Lovastatin 40 mg, Fluvastatin x1 80 mg Fluvastatin 40 mg B1D Pitavastatin 2-4 mg,Berson IEEE LSZ 17% Eon CoenMOGUCA OBJASNJENJA PLEJOTROPNOG EFEKTA STATINA NA KVB aac Snizavaju nivo ukupnog i LDL sr holesterola kao i triglicerida ct * Popravija endotelnu disfunkeiju © Smanjuje responsivnost na angiotenzin II ® Snizava nivo inflamatornih smesenct citokina Direktan antihipertroficki,antioksidantni i antifibroticki efekat na miokardium ® Menja imunu funkciju, metabolizam makrofaga i éelijsku proliferaciju nezavisno1° Podleze metabolizmu — Nepodlede metabolizmu Jetra i GIT* tees oon » simvastatin ene atorvastatinJUPITER Podaci 0 podnosijivosti i sigurnosti rosuvastatina (doza 20 mg) : Placebo Roswvastatin pevalue “Adverse Events {ves0t) t ‘Any Serious adverse event iss 152 om = Muscle weakness stiness, pain Ba 160, 038 + Myopally om Or OE + Rhabdomyolysis 00 or" 7 + Newly diggnosed cancor 35 34 ost + Death from eancer OF oy 0.02, + Gasirointestnal disorders 152 137 0a + Renal disorders 34 60 08 + Bleeding 3 29 04s, = Hepat disorders 21 24 0 Other events, (%) = __Newly diagnosed Gaberes™ 7 EG} Dor + —Taemonthagie soke or or oat “coca ec rlanpebn onsen npr aponlbes “Bier a Nag) Wel 20S: 215207*Statini: monitoring... St Geucl 8-12 nedelja Svakih 6-12 meseci BST a ed Jednom godignje ili prema potrebi (kada pacijent navodi sumnjive simptome) Cried Bl Prema potrebi (kada pacijent navodi ukoéenost, ae osetljivost ili bol u migi¢ima) 8-12 nedelja nakon poéetka/promene terapije Bazalno